Strong M&A (mergers and acquisitions) activity kept this fund in the green while other sectors slumped.
If you had bought the in 2018, you would have captured the beginning of the massive run-up in Big Tech (Apple, Microsoft, Amazon) that defined the early 2020s. best etf to buy 2018
As rates rose, "cash-like" ETFs finally started providing a modest yield without the drama of the stock market. Review Summary: Was 2018 a good year to buy? 2018 Context Long-term Verdict Broad Market (VOO/VTI) Rough end to the year (-4% approx). Strong M&A (mergers and acquisitions) activity kept this
Healthcare often acts as a "defensive" sector during volatility. In 2018, breakthroughs in gene therapy boosted specific biotech ETFs. iShares Nasdaq Biotechnology ETF (IBB) Review Summary: Was 2018 a good year to buy
While still a giant, many investors now prefer the XBI (SPDR S&P Biotech) for its equal-weight approach to smaller, high-growth companies. 3. Short-Term Treasury & Cash (The Safety Net)